Update from top MON Specialists

[william-Indo]

vjhemonc.com/event/mpn-sess...

Highlight from MPN 2022 meeting

[EPguy]

This part stands out:

"community physicians really remember their father’s interferon, short acting, high-dose for CML or melanoma or renal cell. That was very toxic. This (Besremi) is a totally different deal"

We've seen here some Drs are still afraid of IFN.

They make a couple references to the potential immune therapies for CALR ET. These are a most promising category in cancer, but research for Jak2 is farther out.